| Today’s Big NewsJan 8, 2024 |
|
Tuesday, January 23, 2024 | 11am ET / 8am PT Join a cutting-edge conversation on January 23, 2024 with Real Chemistry and Quid as they explore how their partnership has forged a deeper understanding of patient insights. Register now. 
|
|
|
 Thank you to Novartisfor sponsoring our editorial feature: JPM Week 2024
|
|
| By James Waldron Not to be outdone by its Big Pharma peers, Johnson & Johnson has fattened up its antibody-drug conjugate (ADC) pipeline via the acquisition of Ambrx Biopharma for $2 billion. |
|
|
|
By Nick Paul Taylor Merck & Co. has speared an acquisition target, agreeing to pay $680 million for Harpoon Therapeutics and its pipeline of T-cell engagers. The deal will give Merck control of drug candidates that will expand its cancer pipeline and offer opportunities to offset the upcoming loss of Keytruda exclusivity. |
By Annalee Armstrong Vertex Pharmaceuticals’ islet cell diabetes med VX-880, which has shown promise in eliminating the need for insulin in a small group of patients, has been placed on a voluntary hold after two deaths deemed unrelated to treatment occurred in the ongoing trial. |
By Nick Paul Taylor Vertex is severing one of its ties to CRISPR Therapeutics. The big biotech has chosen to opt-out of the diabetes gene-edited stem cell therapy it gained through the acquisition of ViaCyte, leaving CRISPR to take the clinical-phase program forward itself. |
By Max Bayer Just more than two years after launching within Alphabet, Isomorphic has inked two large pharma deals with Eli Lilly and Novartis with nearly $3 billion in combined deal value. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer,James Waldron,Ben Adams The J.P. Morgan Healthcare Conference in San Francisco is back and here at Fierce Biotech, we’re going to bring you all the latest updates live from the life sciences event of the year. |
By Annalee Armstrong The overall deal flow in biopharma tapered off in 2023 but the big companies sure know what they want (what they really, really want), according to a new report from J.P. Morgan. |
By Annalee Armstrong AbbVie CEO Richard Gonzalez wanted one thing and one thing only for Christmas: Cerevel Therapeutics wrapped up quickly and neatly under his Christmas tree. |
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Nick Paul Taylor Novartis danced into a big week in the biopharma calendar with a trio of deals. The Swiss drugmaker is paying $250 million to renew its interest in a cytokine, dropping $185 million on two RNAi cardiovascular disease candidates and handing over $37.5 million to partner with an AI-enabled biotech. |
By Annalee Armstrong Oryzon Genomics will seek the FDA’s advice after a psychiatric drug failed to impact the symptoms or severity of borderline personality disorder, but executives are keen to push forward with refreshed clinical endpoints. |
By Annalee Armstrong Seems the IPO window is open at least a crack, and Metagenomi is ready to sneak through with Arrivent Biopharma hot on its tail. |
By Angus Liu,Zoey Becker,Fraiser Kansteiner,Kevin Dunleavy,Eric Sagonowsky As the J.P. Morgan Healthcare Conference kicked off in San Francisco, EY released its annual report on the industry's dealmaking firepower. Plus, Moderna, bluebird and other companies updated investors on their businesses heading into 2024. |
By Andrea Park After scoring an FDA nod last spring allowing updated versions of its continuous glucose monitors to be integrated into automated insulin delivery systems, Abbott has selected the first such system to pair with its FreeStyle Libre technology. |
By Heather Landi Amazon plans to collaborate with digital health companies to connect customers with virtual care benefits for managing conditions like diabetes and hypertension. The online retail giant tapped virtual-first chronic care provider Omada Health as its first partner. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| |
|
